These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2532073)

  • 41. Remission of acute myelogenous leukemia in elderly patients with prior refractory dysmyelopoietic anemia.
    Murray C; Cooper B; Kitchens LW
    Cancer; 1983 Sep; 52(6):967-70. PubMed ID: 6576847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination chemotherapy of adult acute nonlymphoblastic leukemia.
    Levi JA; Vincent PC; Gunz FW
    Ann Intern Med; 1972 Mar; 76(3):397-403. PubMed ID: 4502024
    [No Abstract]   [Full Text] [Related]  

  • 44. [Cancer curable by chemotherapy: acute myelogenous leukemia].
    Ohno R; Tanimoto M; Morishita Y; Morishima Y; Saito H; Yokomaku S; Nagai T; Kodera Y; Minami S
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1329-34. PubMed ID: 2730046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
    Kornblau SM; Kantarjian H; O'Brien S; Andreeff M; Koller CA; Beran M; Keating M; Estey E
    Leuk Lymphoma; 1998 Jan; 28(3-4):371-5. PubMed ID: 9517508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in acute myeloid leukemia.
    Archimbaud E; Treille-Ritouet D; Guyotat D; Viala JJ; Fiere D
    Leuk Res; 1987; 11(3):281-3. PubMed ID: 3470576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
    Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J; Conroy J; Topolsky D; Crilley P; Kahn SB; Bulova S; Weiss J; Brodsky I
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia.
    Benjamin RS; Keating MJ; Valdivieso M; McCredie KB; Livingston RA; Burgess MA; Rodriguez V; Bodey GP; Gottlieb JA
    Cancer Treat Rep; 1979 Jun; 63(6):939-43. PubMed ID: 380802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
    Kantarjian HM; Jabbour EJ; Garcia-Manero G; Kadia TM; DiNardo CD; Daver NG; Borthakur G; Jain N; Waukau JB; Kwari MI; Ravandi F; Anderson BD; Iizuka K; Jin C; Zhang C; Plunkett WK
    Cancer; 2019 May; 125(10):1665-1673. PubMed ID: 30668890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
    Wielenga JJ; Vellenga E; Groenewegen A; Sonneveld P; Löwenberg B
    Leukemia; 1996 Jan; 10(1):43-7. PubMed ID: 8558936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia.
    Dutcher JP; Riggs CE; Strauman JJ; Link B; Wiernik PH
    Clin Pharmacol Ther; 1989 Apr; 45(4):424-8. PubMed ID: 2702800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose carboplatin in the treatment of hematologic malignancies.
    Vogler WR
    Oncology; 1993 Nov; 50 Suppl 2():42-6. PubMed ID: 8233301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.
    Cantwell BM; Veale D; Rivett C; Ghani S; Harris AL
    Cancer Chemother Pharmacol; 1989; 23(4):252-4. PubMed ID: 2538251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
    Dick FR; Burns CP; Weiner GJ; Heckman KD
    Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of vindesine in patients with acute leukemia.
    Sklaroff RB; Arlin Z; Young CW
    Cancer Treat Rep; 1979; 63(11-12):2063-5. PubMed ID: 294307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.